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Abstract
Bacitracin and the membrane-impermeant thiol reagent 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) are agents known
to inhibit protein disulfide isomerase (PDI), a cell-surface protein critical in HIV-1 entry therefore they are fusion
inhibitors (FI). Here we investigated the possibility that Bacitracin and or DTNB might have other antiviral activities
besides FI. By means of residual activity assays, we found that both compounds showed antiviral activity only to
viruses T-tropic HIV-1 strain. Cell-based fusion assays showed inhibition on HeLa-CD4-LTR-b-gal (CD4) and HL2/3
cells treated with Bacitracin, and DTNB with the latest compound we observed fusion inhibition on both cells but
strikingly in HL2/3 cells (expressing Env) indicating a possible activity on both, the cell membrane and the viral
envelope. A time-of-addition experiment showed that both compounds act on HIV entry inhibition but DTNB also
acts at late stages of the viral cycle. Lastly, we also found evidence of long-lasting host cell protection in vitro by
DTNB, an important pharmacodynamic parameter for a topical microbicide against virus infection, hours after the
extracellular drug was removed; this protection was not rendered by Bacitracin. These drugs proved to be leading
compounds for further studies against HIV showing antiviral characteristics of interest.
Introduction
The pandemic of Human Immunodeficency Virus Tipe
1 (HIV-1) infection, the cause of AIDS, is a public
health issue and ranks among the greatest infectious dis-
ease scourges in history [1]. There were more than 33.3
million people worldwide with HIV-1 infection or AIDS,
according to estimates by the Joint United Nations Pro-
gramme on HIV/AIDS 2009 (UNAIDS).
The use of highly active antiretroviral therapy has dra-
matically reduced morbidi t ya n dm o r t a l i t ya m o n g
patients infected with HIV-1 [2,3]. However, the success
of antiretroviral treatment is frequently limited by the
emergence of HIV-1 drug resistance. Several researchers
have attempted to develop various virucidal agents to
inactivate the cell-free virions and therefore prevent the
sexual transmission of HIV-1 [4-7].
In the early event of HIV-1 infection, the viral glyco-
protein gp120 attaches the virus to the cell by binding
to its receptor CD4 on cells of the host’si m m u n es y s -
tem. Another cell-surface protein was found to be
involved in HIV-1 entry, the oxidoreductase protein dis-
ulfide isomerase (PDI) [8,9]. PDI has been described to
play a role in host cell uptake of some toxins, bacteria,
parasite [10] and virus modulating the exchange of pro-
tons between a cell-surface associated donor (PDI) and
viral proteins by catalyzes thiol-disulfide SH/-S-S-
interchange [11,12].
Besides the observation that PDI inhibition blocks the
HIV replicative cycle [13] by conformational changes,
gp120 interacts with the enzyme PDI and the chemo-
kine co-receptors form a PDI-CD4-gp120-chemokine
complex also prevent HIV envelope mediated fusion [9]
PDI can reach the complex and reduce disulfide bonds
in gp120 [14] that involves cleavage of two of the nine
disulfide bonds of gp120 [15-17], which causes key con-
formational changes in gp120 and activate gp41 enhan-
cing the fusogenic potential of the viral envelope. It has
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brought about by introducing membrane impermeant
sulfhydryl agents that can block the redox function of
PDI, acting inhibiting PDI, to prevent the viral entry
[8,18].
Studies reported that the thiol reagent 5,5’-dithiobis-2-
nitrobenzoic acid (DTNB) [8,9], and Bacitracin were
commonly used as inhibitors of PDI activity. These
agents will stop the generation of two free thiols in a
gp120 and an oxidized form of CXXC motif in PDI,
blocking HIV-1 infection [19]. More recently, were
showed that these inhibitors altered the HIV receptor-
dependent gp41-mediated fusion process per se at a
post-CD4 binding step, particularly DTNB, prevents
gp41 from assuming the 6-helix bundle conformation
that drives fusion [15-17], but the effect was temporally,
only was observed when the agents were present at the
time of virus-cell interaction [8,9]. It is speculated that
inhibition if HIV infectivity by Bacitracin could arise
because of one of two effects [20]. First, Bacitracin
could inhibit PDI by competing with substrate binding,
especially by competing for the substrate-binding site on
the b’ domain. Second, PDI activity could be inhibited
by the metal ions that bacitracin is known to bind.
These metal ions could be coordinated by the active site
cysteines of the catalytic domains of PDI, decreasing
their activity.
It was reported that the DTNB causes 100% inhibition
of soluble PDI activity at 1.0 mM concentration [8,9].
The mechanisms is not yet been completely elucidated
however, it has been reported the DTNB acting two
conformations, there were, three, two hydrogen bonds
formed; thiol group of Cys37 and backbone-oxygen
atom of Phe80 in PDI enzyme interacts with the two
different atom of sulfur (S2 and S1) in DTNB and side
chain nitrogen atom of Arg101 was also involved in the
hydrogen bond interaction with O3 atom of DTNB [19]
Previous studies described molecular docking simula-
tion to investigate the binding mechanisms of action for
Bacitracin and DTNB or fusion inhibition by reorganiza-
tion of the conformation of Env, however the action as
antiviral and the importance of HIV receptors (CXCR4
on CD4+ lymphocytes) has not been clearly established.
For that reason and searching for other antiviral activ-
ities that these leading compounds might have, we also
tested if these compounds have long lasting protection
against viral infection on uninfected host cells even
hours after the compounds were removed form the
media which is an important pharmacodynamic para-
meter investigated during the development of a topical
microbicide agent. In addition we evaluated the stages
of the viral cycle to elucidate the target sites of these
compounds.
Methods
Reagents, cells and HIV-1 isolates
The following reagents were obtained through AIDS
Research and Reference Reagent Program, NIH: HeLa-
CD4-LTR-b-gal (CD4) cells from Dr. Michael Emerman;
HL2/3 (Env) cells from Dr. Barbara K. Felber and
D r .G e o r g eN .P a v l a k i s ;H I V - 1 IIIB,H I V - 1 BaL and Fusion
Inhibitor T-20, Integrase Inhibitor 118-D-24 and Pro-
tease Inhibitor Amprenavir from Dr. Suzanne Gartner,
Dr. Mikulas Popovic and Dr. Robert Gallo. DTNB and
Bacitracin were obtained from Sigma-Aldrich. UC781, a
NNRTI, was kindly donated by Dr. Gadi Borkow.
Cytotoxicity assays
A stock solution of DTNB and Bacitracin was two-fold
diluted to desired concentrations in growth medium and
subsequently added into wells containing 5 × 10
4 HeLa-
CD4-LTR-b-gal cells. Microtiter plates were incubated
at 37°C in a 5% CO2 air humidified atmosphere for
24 hours. Assessments of cell viability were carried out
using a CellTiter-Glo
® Luminescent Cell Viability Assay
(Promega). Cytotoxicity was evaluated based on the per-
centage cell survival relative to the infection obtained in
the absence of any compound.
Virucidal activity assays
Serial two-fold dilutions of DTNB, Bacitracin or just
media as control were added to HIV-1IIIB or HIV-1BaL
cell-free virus. After incubation for 5 min at room tem-
perature, the mixtures of compounds with virus were
centrifuged three times at 10,000 rpm, the supernatant
fluids removed, and the pellets washed three times. The
final pellets were resuspended in DMEM and placed
into 96-well plates with HeLa-CD4-LTR-b-gal cells. The
cells were incubated in a 5% CO2 humidified incubator
at 37°C for 24 h. Assessment of HIV-1 infection was
performed with the Beta-Glo Assay System. The percen-
tage of residual infectivity after DTNB, Bacitracin or
media as control was calculated with respect to the con-
trol. The 50% inhibitory concentration (IC50)w a s
defined according to the percentage of infectivity inhibi-
tion relative to the positive control.
Cell-based fusion assay
HeLa-derived HL2/3 cells, which express the HIV-1HXB2
Env, Tat, Gag, Rev, and Nef proteins, were co-cultured
with HeLa-CD4-LTR-b-gal cells at a 1:1 cell density
ratio (5 × 10
4 cells/well each) for 24 h in the absence or
presence of two-fold dilutions of DTNB, Bacitracin,
UC781, and T-20 in order to examine whether the com-
pounds interfered with the binding process of HIV-1
Env and the CD4 receptor. Also, both HeLa-CD4-LTR-
b-gal and HL2/3 cells were exposed independently only
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washed twice thoroughly to eliminate residual com-
pound before co-cultivating with the other cell line.
Upon fusion of both cell lines, the Tat protein from
HL2/3 cells activates b-galactosidase indicator gene
expression in HeLa-CD4-LTR-b-gal cells
20. b-gal
activity was quantified with the Beta-Glo Assay System
(Promega). The percentage of inhibition of HL2/3-HeLa
CD4 cell fusion was calculated with respect to the posi-
tive control of untreated cells.
Time-of-addition experiments
HeLa-CD4-LTR-b-gal cells were infected with 10
5
TCID50 of HIV-1IIIB cell-free virus with a 0.2-0.5 MOI.
Bacitracin (3.5 mM), DTNB (6 mM), T-20 (100 μM),
UC781 (70 nM), 118-D-24 (120 μM) and Amprenavir
(0.1 mM) were then added upon HIV-1 inoculation (time
zero) or at various time points post-inoculation. The
reference compounds were added at a concentration sev-
eral times their EC50 required to reduce by 50% the cyto-
pathicity of HIV-1IIIB. Infection inhibition was quantified
after 24 h of incubation, by measuring b-gal activity of
the target cells with the Beta-Glo Assay System.
Cell-Protection Assays
HeLa-CD4-LTR-b-gal cells were incubated with DTNB
(12.6 mM) or Bacitracin (5.3 mM) for 30 minutes and
subsequently the cells were washed with PBS three
times. Then, the cells were infected with 10
5 TCID50 of
HIV-1IIIB cell-free virus with a 0.2-0.5 MOI at different
times (1, 3, 6, 10 and 24 h) of exposure to the drugs.
The inhibition of infection was quantified after 24 h by
measuring b-gal activity with the Beta-Glo Assay
System.
Statistical analysis
Graphs were done with SigmaPlot 10.0 software and the
values shown are means ± standard deviations from
three separate experiments, each of which was carried
out in duplicate.
Results
Range of virucidal activity
To study the effect that DTNB or Bacitracin have over the
virus itself, M-tropic (HIV-1BaL) and T-tropic (HIV-1IIIB)
isolates were treated with different concentrations of PDI
inhibitors the mixtures were centrifuged three times at
10,000 rpm in an eppendrof centrifuge. After removal of
the supernatant fluids with or without (control) com-
pounds, the pellets were washed three times. The final
pellets were placed into 96-well plates with HeLa-CD4-
LTR-b-gal cells. Assessment of HIV-1 infection was made
with a luciferase-based assay. The percentage of residual
infectivity after treatment was calculated with respect to
the positive control of untreated virus. The assay was per-
formed in triplicate; the data points represent the mean,
and the solid lines are nonlinear regression curves done
with SigmaPlot 10.0 software.by centrifugation, the resi-
dual infectivity of the cell-free viruses was quantified by a
luciferase-based assay using indicator cell lines. As shown
in Figure 1(A-B), pretreatment with Bacitracin or DTNB
reduced the infectivity of T-tropic (HIV-1IIIB)a f t e rj u s t
Figure 1 Residual Activity on HIV-1 strains. A, B) HIV-1IIIB and C, D) HIV-1BaL cell-free viruses were exposed to serial dilutions of A, C)
Bacitracin and B, D) DTNB for 5 minutes. The viruses were then ultracentrifuged, washed three times and added to HeLa-CD4-LTR-b-gal cells
After 24 hours, b-gal activity was measured. Percentage values are relative to the positive control (no compound pretreatment).
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ment did not show a significant inhibition activity over M-
tropic (HIV-1BaL). The concentration of Bacitracin and
DTNB at which HIV-1IIIB infectivity was inhibited by 50%
(IC50) was 1.18 mM and 2.60 mM, respectively, Bacitracin
showed a higher therapeutic index (TI), more than three
times higher than the TI showed by DTNB. However,
cytotoxic concentration which 50% of cell dead (CC50)
were 30.37 and 19.77 for Bacitracin and DTNB respectly
(Table 1).
Inhibition of Env/CD4-mediated membrane fusion
A cell-based fusion assay was used to mimic the gp120-
CD4-mediated fusion process between HIV-1 and the
host cell. The effector cells were HL2/3 cells, which
express HIV-1 Env on their surfaces and Tat protein in
their cytoplasms [21], and experiments were performed
to determinate whether DTNB and Bacitracin tended to
act directly either on the HeLa-CD4-LTR-b-gal (CD4)
cells or HL2/3 (Env) cells or boths cells when inhibiting
fusogenic activity. When HeLa-CD4-LTR-b-gal (CD4)
cells were first exposed to the compounds and then
HL2/3 (Env) cells were added, both Bacitracin (Figure
2A) and DTNB (Figure 2B) blocked fusion in a dose
response manner between both cells; the same happened
when HL2/3 (Env) cells were first exposed to the com-
pounds and then HeLa-CD4-LTR-b-gal (CD4) cells were
added (Figure 2A-B). A significant lower dose of Baci-
tracin was required to reach an observable decrease in
fusogenic activity in HeLa-CD4-LTR-b-gal (CD4) cells
than the dose needed to pretreat HL2/3 (Env) cells (p =
0.09); on the other hand, a significant lower dose of
DTNB was needed to inhibit the fusogenic activity when
HL2/3 (Env) cells were pretreated compared to the pre-
treatment of HeLa-CD4-LTR-b-gal (CD4) cells (p =
0.009). In addition the assays were performed, while the
exposure of Bacitracin and DTNB to HeLa-CD4-LTR-b-
gal (CD4) or HL2/3 (Env) cells, separately, during 30
minutes only, following by extracellular compound
removal by washing the cells. Results showed a signifi-
cant lower dose was required to inhibit fusogenic activ-
ity when HL2/3 (Env) cells were pretreated with DTNB
during 24 hours than the 30 minutes pretreatment
before mixing to HeLa-CD4-LTR-b-gal (CD4) cells
exposure (p = 0.007). Our data, as well as data from
others laboratories, support the concept that thiol/
disulfide rearrangement in gp120 catalyzed by PDI
occurs post-CD4 engagement [17]. Known antiretroviral
drugs were used as controls, such as UC781 (NNRTI),
which did not inhibit cell fusion in these cell-based
fusion assays (Figure 2C), and T-20 (FI), which did inhi-
bit cell fusion in all assays, except when exposed to
HeLa-CD4-LTR-b-gal (CD4) cells for only 30 minutes
(Figure 2D).
Time (Site) of Intervention
To further determine the antiviral target of Bacitracin
and DTNB, a time-of-addition experiment was per-
formed using a single cycle infection assay. Several anti-
retroviral drugs were chosen as controls as they point
out different stages of the viral cycle (fusion or entry,
retrotranscription, protease activity, and integration to
the genome). As seen in Figure 3(A-F), the antiviral
activity of T-20, UC781, 118-D-24 and Amprenavir
started to decline after the cycle stage that the antiviral
target has passed. The fusion inhibitor’s activity declined
after 2 h (Figure 3C), RT inhibitor after 15 h (Figure
3D), integrase inhibitor after 18 h (Figure 3E), and pro-
tease inhibitor after 18 h (Figure 3F). Bacitracin retained
its antiviral activities during 2 h (Figure 3A) as a fusion
inhibitor after the HIV inoculation. On the other hand,
15 hours after HIV inoculation, the antiviral activity of
DTNB started to decrease (Figure 3B), which is the time
period of viral entry and integration stages. Also, the
antiviral activity of DTNB regained strength at 24 hours
post-HIV inoculation, which corresponds to viral pro-
tease stage [22].
Cell-Protection Assays
HeLa cells were pretreated with Bacitracin and DTNB
for 30 minutes and subsequently exposed to HIV-1IIIB at
different post-infection times until 48 hours to measure
cell protection without extracellular drug. As shown in
Figure 4(A), after extracellular Bacitracin is removed,
there is no cellular protection against infectivity, while
DTNB protection against infection to cells after removal
of extracellular drug, was retained until 10 hours.
Discussion
PDI inhibition blocks the HIV early replicative cycle
[7,13] and HIV entry occur at 3 different steps: CD4
binding, the gp41 mediated membrane fusion process,
and during uncoating events. Thus conformational
changes, gp120 interacts with the enzyme PDI and the
chemokine co-receptors form a PDI-CD4-gp120-chemo-
kine complex also prevent HIV envelope mediated
fusion to the host cell [8,9,14,17,23].
DTNB and Bacitracin are PDI inhibitors that previously
reported activity against HIV-1 T-tropic strains, which
have CXCR4 co-receptor dependence (CXCR4) [8,9].
Table 1 CC50 and virucidal IC50 values for HIV-1 strains
CC50 (mM) IC50 (mM) TI
(HIV-1IIIB/HIV-1Ba-L)
HIV-1IIIB HIV-1Ba-L
Bacitracin 30.37 1.18 > 30.37 25.73/< 1
DTNB 19.77 2.60 > 19.77 7.60/< 1
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the catalytic sites of PDI and abolishes its capacity for
cleaving disulfides, whereas Bacitracin inhibits both its
reductive and oxidative functions [14,24]. In this paper we
found that both compounds showed antiviral and virucidal
activities in a dose-dependent manner. However T-tropic
(HIVIIIB) strains which has CXCR4 co-receptor were sus-
ceptible to both compounds and not to the M-tropic
(HIV-BaL) strain (Figure 1A-D) due probably at the
increased of negative charge (T-tropic) in variable region
(V3) of human immunodeficiency virus type 1 (HIV-1)
envelope gp120 subunit participates in determination of
viral infection coreceptor tropism [25-27].
Furthermore, cell-based fusion assays [28] were per-
formed for these compounds, using HeLa-CD4-LTR-b-
gal cells [29] and H2/3 (Env-expressing) cells [21],
where co-culture expressing cells results in efficient cell
fusion within 6-12 hours. We found that both Bacitracin
and DTNB showed inhibition of cell-cell fusion in a
dose-dependent manner when exposed to HeLa-CD4-
LTR-b-gal cells (Figure 2A-B). These results are similar
to those presented by Fenouillet et al [14], where PDI
inhibitors as well as anti-PDI antibodies, were used to
inhibit cell-cell fusion assays. However exposure to
HeLa-CD4-LTR-b-gal cells showed no significant differ-
ence on cell-cell fusion on either the 24 hour or the
30 minute exposure assay which is the time the process
of conformational changes of gp120 after CD4 bonding
takes place [30]. Alternatively, long-term exposure
( 2 4h o u r s )o fD T N Bo nH L 2 / 3( E n v - e x p r e s s i n g )c e l l s
and then mixing them with CD4 cells showed significant
inhibition of cell-cell fusion as showed in Figure 2B.
This effect of Bacitracin and DTNB markedly on Env
expressing cells has never been reported.
Also, our findings indicate that Bacitracin and DTNB act
differently on HeLa-CD4-LTR-b-gal cells and HL2/3 (Env-
expressing) cells, given that Bacitracin has more effect on
HeLa-CD4-LTR-b-gal cells but less effect against HL2/3
(Env-expressing) cells fusion’s activity, however DTNB has
cell-cell fusion inhibition effect on HeLa-CD4-LTR-b-gal
cells but predominantly on HL2/3 (Env-expressing) cells.
This data confirmed that both compounds act on the HIV
receptor dependent gp41 mediated fusion process per se
through inhibition of a post-CD4 binding step that has
antiviral effects and virucidal action [14]. However our
results with Bacitracin showed that has a better inhibition
Figure 2 Inhibition of Env/CD4-mediated membrane fusion. b-gal activity was measured after CD4 and Env cells were co-cultured when
exposed to A) Bacitracin, B) DNTB, C) UC781 and D) T-20, in different circumstances: (red) CD4 cells were exposed to the compound and co-
cultured with Env cells for 24 hours. (green) Env cells were exposed to the compound and co-cultured with CD4 cells for 24 hours. (purple) CD4
cells were exposed to the compound for 30 minutes, washed, and co-cultured with Env cells for 24 hours. (blue) Env cells were exposed to the
compound for 30 minutes, washed, and co-cultured with CD4 cells for 24 hours. Percentage values are relative to the positive control (no
treatment). The data represent the means ± standard deviations from three separate experiments, each of which was carried out in duplicate.
Lara et al. Virology Journal 2011, 8:137
http://www.virologyj.com/content/8/1/137
Page 5 of 8effect on the host CD4 cell acting only as fusion inhibitor
on CD4 cells [20] but also having an inhibition effect on
env expressing cells.
In addition, to further determine the antiviral target of
Bacitracin and DTNB, a time-of addition experiment
was used to delimit the stage(s) of the viral life cycle
that is blocked by these compounds separately, compar-
ing it with several antiretroviral drugs as controls that
point out different stages of the viral cycle [31-36]
(Figure 3C-F). Our findings suggest that Bacitracin inhi-
bits HIV-1 infection at stage of viral entry or fusion
(Figure 3A), however DTNB acts at a time period
between and including viral entry and other later stages
(Figure 3B). DTNB results shows that has probably an
antiviral function affect on protease activity, this results
are also according to Lebon [22]. This is the first time,
to our knowledge, that the activity of this compound
has been associated to HIV-1 life cycle stages besides
Figure 3 Time of Intervention in HIV-1 Life Cycle. HeLa/CD4-LTR-b-gal cells were infected with HIV-1IIIB cell-free virus before A) Bacitracin (3.5
mM), B) DTNB (6 mM), C) T-20 (100 μM), D) UC781 (70 nM), E) 118-D-24 (120 μM) and F) Amprenavir (0.1 mM), were added upon HIV-1
inoculation (time zero) or at various time points post-inoculation and b-gal activity was measured following 24 hr of incubation. Percentage
values are relative to the positive control (no treatment). The data represent the means ± standard deviations from three separate experiments,
each of which was carried out in duplicate.
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of PDI using small interfering RNA had only a small
effect on infection or cell fusion mediated by HIV-1,
suggesting that other thiol active enzymes at the cell
surfaces are involved in reduction of the HIV envelope
glycoprotein, that is therefore an interesting result.
Lastly, in order to provide a barrier to infection by resi-
dual active virus on uninfected cells, we evaluated the
long-term effectiveness of the compound, which is an
important pharmacodynamic parameter tested for the
development of a topical agent [37], and is defined as the
length of time that infection is suppressed following brief
exposure to the antiviral agent. Ideally, a microbicide
should remain effective for several hours after topical
application. These compounds should be able to give cell
protection for several hours after the removal of the extra-
cellular drug [38] Although Bacitracin did not show cell
protection (Figure 4A), DTNB on the other hand, showed
lasting cell protection (50% infection inhibition) even 10
hours after compound was washed and removed from the
indicator cells (Figure 4B). These results are consistent
with a time-of addition experiment that showed that
DTNB act after viral entry suggesting that DTNB some-
how bonds to target cell strongly and though DTNB’sP D I
bonding activity is not discarded, other cell sites could be
participating. Previous reports showed DTNB only has
effect when anti-PDI was present at the time of virus-cell
interaction (Ryser et al., 1994). Our results demonstrated
that exposure of uninfected cells to DTNB renders these
cells refractory to subsequent HIV-1 infection, even in the
absence of a continued extracellular presence of the drug.
Thus, DTNB may serve to minimize the sexual transmis-
sion of HIV-1 from infected to noninfected individuals.
In summary, although both, Bacitracin and DTNB, are
classified as fusion inhibitors of cell PDI, our findings
suggest new data. The data presented here are novel in
that they prove that both Bacitracin and DTNB (besides
acting on cell PDI), are also virucidal agents against T-
tropic HIV-1 infection, and DTNB acts not only at early
viral cycle stages but also at late stages with long lasting
effects on the CD4 cells.
Based on our results and the above requirements,
DTNB could be considered as a leading compound to
further studies to determine their potential use as thera-
peutic agents in HIV-1 infection, especially due to their
virucidal and fusion inhibitor properties.
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Figure 4 Cell Protection Against HIV-1 Infection. b-gal activity
was measured after HeLa/CD4-LTR-b-gal cells were exposed to
A) Bacitracin (5.3 mM) and B) DTNB (12.6 mM) for 30 minutes,
washed and exposed to HIV-1IIIB cell-free virus at various time points
post-treatment. Percentage values are relative to the positive control
(no treatment). The data represent the means ± standard deviations
from three separate experiments, each of which was carried out in
duplicate.
Lara et al. Virology Journal 2011, 8:137
http://www.virologyj.com/content/8/1/137
Page 7 of 8References
1. Fauci AS: The AIDS epidemic–considerations for the 21st century. N Engl
J Med 1999, 341(14):1046-1050.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and
mortality among patients with advanced human immunodeficiency
virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998,
338(13):853-860.
3. Vittinghoff E, Scheer S, O’Malley P, Colfax G, Holmberg SD, Buchbinder SP:
Combination antiretroviral therapy and recent declines in AIDS
incidence and mortality. J Infect Dis 1999, 179(3):717-720.
4. Balzarini J, Naesens L, Verbeken E, et al: Preclinical studies on
thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998,
12(10):1129-1138.
5. Fauci AS: Multifactorial nature of human immunodeficiency virus disease:
implications for therapy. Science 1993, 262(5136):1011-1018.
6. Pantaleo G, Graziosi C, Fauci AS: The role of lymphoid organs in the
pathogenesis of HIV infection. Semin Immunol 1993, 5(3):157-163.
7. Van DL, Rosenberg ZF: Microbicides and barrier methods in HIV
prevention. AIDS 1999, 13(Suppl A):S85-S92.
8. Ryser HJ, Levy EM, Mandel R, DiSciullo GJ: Inhibition of human
immunodeficiency virus infection by agents that interfere with thiol-
disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci
USA 1994, 91(10):4559-4563.
9. Gallina A, Hanley TM, Mandel R, et al: Inhibitors of protein-disulfide
isomerase prevent cleavage of disulfide bonds in receptor-bound
glycoprotein 120 and prevent HIV-1 entry. J Biol Chem 2002,
277(52):50579-50588.
10. Santos CX, Stolf BS, Takemoto PV, et al: Protein disulfide isomerase (PDI)
associates with NADPH oxidase and is required for phagocytosis of
Leishmania chagasi promastigotes by macrophages. J Leukoc Biol 2009,
86(4):989-998.
11. Edman JC, Ellis L, Blacher RW, Roth RA, Rutter WJ: Sequence of protein
disulphide isomerase and implications of its relationship to thioredoxin.
Nature 1985, 317(6034):267-270.
12. Gilbert HF: Protein disulfide isomerase and assisted protein folding. J Biol
Chem 1997, 272(47):29399-29402.
13. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998, 93(5):681-684.
14. Fenouillet E, Barbouche R, Courageot J, Miquelis R: The catalytic activity of
protein disulfide isomerase is involved in human immunodeficiency
virus envelope-mediated membrane fusion after CD4 cell binding.
J Infect Dis 2001, 183(5):744-752.
15. Barbouche R, Lortat-Jacob H, Jones IM, Fenouillet E: Glycosaminoglycans
and protein disulfide isomerase-mediated reduction of HIV Env. Mol
Pharmacol 2005, 67(4):1111-1118.
16. Barbouche R, Miquelis R, Jones IM, Fenouillet E: Protein-disulfide
isomerase-mediated reduction of two disulfide bonds of HIV envelope
glycoprotein 120 occurs post-CXCR4 binding and is required for fusion.
J Biol Chem 2003, 278(5):3131-3136.
17. Markovic I, Stantchev TS, Fields KH, et al: Thiol/disulfide exchange is a
prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion
during viral entry. Blood 2004, 103(5):1586-1594.
18. Ryser HJ, Fluckiger R: Progress in targeting HIV-1 entry. Drug Discov Today
2005, 10(16):1085-1094.
19. Gowthaman U, Jayakanthan M, Sundar D: Molecular docking studies of
dithionitrobenzoic acid and its related compounds to protein disulfide
isomerase: computational screening of inhibitors to HIV-1 entry. BMC
Bioinformatics 2008, 9(Suppl 12):S14.
20. Hatahet F, Ruddock LW: Modulating proteostasis: peptidomimetic
inhibitors and activators of protein folding. Curr Pharm Des 2009,
15(21):2488-2507.
21. Ciminale V, Felber BK, Campbell M, Pavlakis GN: A bioassay for HIV-1
based on Env-CD4 interaction. AIDS Res Hum Retroviruses 1990,
6(11):1281-1287.
22. Lebon F, Ledecq M: Approaches to the design of effective HIV-1 protease
inhibitors. Curr Med Chem 2000, 7(4):455-477.
23. Barbouche R, Miquelis R, Jones IM, Fenouillet E: Protein-disulfide
isomerase-mediated reduction of two disulfide bonds of HIV envelope
glycoprotein 120 occurs post-CXCR4 binding and is required for fusion.
J Biol Chem 2003, 278(5):3131-3136.
24. Mandel R, Ryser HJ, Ghani F, Wu M, Peak D: Inhibition of a reductive
function of the plasma membrane by bacitracin and antibodies against
protein disulfide-isomerase. Proc Natl Acad Sci USA 1993, 90(9):4112-4116.
25. Naganawa S, Yokoyama M, Shiino T, et al: Net positive charge of HIV-1
CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity.
PLoS One 2008, 3(9):e3206.
26. Trujillo JR, Goletiani NV, Bosch I, et al: T-tropic sequence of the V3 loop is
critical for HIV-1 infection of CXCR4-positive colonic HT-29 epithelial
cells. J Acquir Immune Defic Syndr 2000, 25(1):1-10.
27. Trujillo JR, Rogers RA, Brain JD: Shared antigenic epitopes on the V3 loop
of HIV-1 gp120 and proteins on activated human T cells. Virology 1998,
246(1):53-62.
28. Yang QE, Stephen AG, Adelsberger JW, et al: Discovery of small-molecule
human immunodeficiency virus type 1 entry inhibitors that target the
gp120-binding domain of CD4. J Virol 2005, 79(10):6122-6133.
29. Kimpton J, Emerman M: Detection of replication-competent and
pseudotyped human immunodeficiency virus with a sensitive cell line
on the basis of activation of an integrated beta-galactosidase gene.
J Virol 1992, 66(4):2232-2239.
30. Jones PL, Korte T, Blumenthal R: Conformational changes in cell surface
HIV-1 envelope glycoproteins are triggered by cooperation between cell
surface CD4 and co-receptors. J Biol Chem 1998, 273(1):404-409.
31. Hombrouck A, Van RB, Michiels M, et al: Preclinical evaluation of 1H-
benzylindole derivatives as novel human immunodeficiency virus
integrase strand transfer inhibitors. Antimicrob Agents Chemother 2008,
52(8):2861-2869.
32. Witvrouw M, Fikkert V, Pluymers W, et al: Polyanionic (i.e., polysulfonate)
dendrimers can inhibit the replication of human immunodeficiency virus
by interfering with both virus adsorption and later steps (reverse
transcriptase/integrase) in the virus replicative cycle. Mol Pharmacol 2000,
58(5):1100-1108.
33. Auwerx J, Stevens M, Van Rompay AR, et al: The
phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT)
inhibitor MSK-076 selects for a resistance mutation in the active site of
human immunodeficiency virus type 2 RT. JV i r o l2004,
78(14):7427-7437.
34. Stevens M, Pannecouque C, De CE, Balzarini J: Novel human
immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-
HIV action. Antimicrob Agents Chemother 2003, 47(10):3109-3116.
35. Svarovskaia ES, Barr R, Zhang X, et al: Azido-containing diketo acid
derivatives inhibit human immunodeficiency virus type 1 integrase in
vivo and influence the frequency of deletions at two-long-terminal-
repeat-circle junctions. J Virol 2004, 78(7):3210-3222.
36. Zhang X, Pais GC, Svarovskaia ES, et al: Azido-containing aryl beta-diketo
acid HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2003,
13(6):1215-1219.
37. Lara HH, Ixtepan-Turrent L, Garza-Trevino EN, Rodriguez-Padilla C: PVP-
coated silver nanoparticles block the transmission of cell-free and cell-
associated HIV-1 in human cervical culture. J Nanobiotechnology 2010,
8:15.
38. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G: Blocking of cell-free
and cell-associated HIV-1 transmission through human cervix organ
culture with UC781. AIDS 2003, 17(5):653-661.
doi:10.1186/1743-422X-8-137
Cite this article as: Lara et al.: Antiviral propierties of 5,5’-dithiobis-2-
nitrobenzoic acid and bacitracin against T-tropic human
immunodeficiency virus type 1. Virology Journal 2011 8:137.
Lara et al. Virology Journal 2011, 8:137
http://www.virologyj.com/content/8/1/137
Page 8 of 8